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Abstract 
Atherosclerosis (AS), the underlying cause of most cardiovascular events, is one of the most common 
causes of human morbidity and mortality worldwide due to the lack of an efficient strategy for targeted 
therapy. In this work, we aimed to develop an ideal biomimetic nanoparticle for targeted AS therapy. 
Methods: Based on macrophage “homing” into atherosclerotic lesions and cell membrane coating 
nanotechnology, biomimetic nanoparticles (MM/RAPNPs) were fabricated with a macrophage membrane 
(MM) coating on the surface of rapamycin-loaded poly (lactic-co-glycolic acid) copolymer (PLGA) 
nanoparticles (RAPNPs). Subsequently, the physical properties of the MM/RAPNPs were characterized. 
The biocompatibility and biological functions of MM/RAPNPs were determined in vitro. Finally, in AS 
mouse models, the targeting characteristics, therapeutic efficacy and safety of the MM/RAPNPs were 
examined. 
Results: The advanced MM/RAPNPs demonstrated good biocompatibility. Due to the MM coating, the 
nanoparticles effectively inhibited the phagocytosis by macrophages and targeted activated endothelial 
cells in vitro. In addition, MM-coated nanoparticles effectively targeted and accumulated in atherosclerotic 
lesions in vivo. After a 4-week treatment program, MM/RAPNPs were shown to significantly delay the 
progression of AS. Furthermore, MM/RAPNPs displayed favorable safety performance after long-term 
administration. 
Conclusion: These results demonstrate that MM/RAPNPs could efficiently and safely inhibit the 
progression of AS. These biomimetic nanoparticles may be potential drug delivery systems for safe and 
effective anti-AS applications. 
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Introduction 
Atherosclerosis (AS) is a typical chronic 
inflammatory vascular disease characterized by the 
gradual thickening of arterial walls [1,2]. It is the 
predominant pathological onset of cardiovascular 
diseases (CVDs), the main cause of death in many 
parts of the world [3,4]. Strong evidence has indicated 
that oral statins reduce the risk of atherosclerotic CVD 
for primary and secondary prevention [5]. However, 
these oral drug therapies suffer from a number of 
issues, including poor bioavailability, slow 
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therapeutic efficacy, and serious side effects. Targeted 
drug delivery by nanotechnology has been 
successfully used for the systemic delivery of a variety 
of drug molecules, in many cases demonstrating an 
enhancement in therapeutic efficacy and mitigation of 
side effects compared to freely administered drugs 
[6-8]. Recent advances have shown the potential of 
nanomedicine-based treatment strategies for 
cardiovascular diseases [9-12]. However, like any 
strategy, there are limitations on the use of targeted 
drug delivery by nanoparticles (NPs). Clearance by 
the immune system before a nanoparticle can reach its 
target is one of the major hurdles that almost all 
platforms must overcome [13-15]. 
In recent years, cell membrane coating 
nanotechnology has emerged as a promising 
therapeutic platform [16-18]. By fusing natural cell 
membranes onto synthetic NPs, these NPs inherit the 
specific biological functions of the source cells, such as 
long circulation and disease-relevant targeting [19,20]. 
For instance, Tasciotti et al. reported the first 
leukocyte membrane-coated nanoparticles that 
enhanced circulation time and improved tumoritropic 
accumulation [21]. Zhang et al. recently reported 
neutrophil membrane-coated nanoparticles to 
alleviate inflammatory arthritis and platelet 
membrane-coated metal-organic framework 
nanoparticles to target gene silencing in vivo [22,23]. 
Most recently, cell membrane coating nanotechnology 
has been applied to treat certain cardiovascular 
diseases [24]. For instance, it has been reported that 
platelet membrane-coated NPs have been applied to 
detect and treat atherosclerosis [25,26]. In our 
previous study, red blood cell (RBC)-coated 
nanoparticles enabled the safe and efficient 
management of atherosclerosis [27]. These works 
provide a promising platform and lay the foundation 
for exploiting more sophisticated cell membrane- 
based nanotherapeutics against atherosclerosis. 
Macrophages are large and highly versatile 
white blood cells that intrinsically work as major 
cellular effectors in inflammatory and tissue repair 
processes [28,29]. In previous studies, macrophage 
membrane-coated NPs have demonstrated high 
targeted delivery efficiency to various inflammatory 
diseases as well as decent therapeutic efficacy, 
including rheumatoid arthritis, cancer and sepsis 
[30-34]. Many studies have shown that macrophages 
also play a major role in the pathogenesis of AS 
[35-37]. During the early stage of AS, macrophage 
colony-stimulating factors and other differentiation 
factors drive monocytes to differentiate into 
macrophages. During the development of AS, 
macrophages promote plaque formation [38]. In fact, 
surface proteins on the macrophage membrane play a 
dominant role in AS pathology [39]. In particular, 
integrin α4β1, for its “homing” into atherosclerotic 
lesions, can actively bind to vascular cell adhesion 
molecule-1 (VCAM-1), which is highly expressed in 
the inflamed endothelium [30,40]. In addition, a 
recent study reported that macrophage membrane- 
coated nanoparticles have the ability to target AS [41]. 
This evidence indicates that macrophages have an 
inherent affinity for atherosclerotic lesions, suggesting 
that a macrophage membrane-coated drug delivery 
system may be a powerful platform for the targeted 
treatment of AS. 
Therefore, in this study, we sought to construct 
macrophage membrane (MM)-coated biomimetic 
nanoparticles for the targeted therapy of AS. 
Rapamycin (RAP) is an inhibitor of the mammalian 
target of RAP (mTOR) pathway, which exhibits 
multiple pharmacological functions, including 
anti-inflammatory and anti-proliferative activities and 
autophagy activation [42]. Various RAP-based agents, 
including oral drugs and nanomedicines, have been 
widely used to manage atherosclerosis [43-45]. 
Therefore, RAP was used as a model drug in this 
work. Specifically, we camouflaged poly(lactic-co- 
glycolic acid) (PLGA) NPs loaded with RAP 
(RAPNPs) with MMs for the targeted and efficient 
management of atherosclerosis (Figure 1). We 
hypothesized that the resulting MM-coated RAPNPs 
(MM/RAPNPs) could be targeted towards and 
accumulate within atherosclerotic plaques to locally 
release antiatherosclerotic drugs, thereby inhibiting 
the progression of AS. 
Methods 
Materials 
RAP and PLGA (MW 90000, 50:50) were 
purchased from Dalian Meilun Biotechnology Co., 
Ltd. (Dalian, Chia). 1,19-Dioctadecyl-3,3,39,39-tetra-
methylindodicarbocyanine perchlorate (DiD) was 
purchased from Biotium Inc. (Fremont, US). DiO, 
DAPI, Cell Total Protein Extraction kits and 
Membrane Protein Extraction kits were supplied by 
Beyotime Institute of Biotechnology (Jiangsu, China). 
The CellTiter 96TM AQueous One Solution Cell 
Proliferation Assay (MTS) was purchased from 
Thermo Fisher Scientific (SanJose, CA, USA). 
Lipopolysaccharide (LPS) was purchased from 
Solarbio (Beijing, China). The mouse glycoprotein 
ELISA kit, mouse TNF-α ELISA kit and mouse IL-6 
ELISA kit were purchased from Wuhan Colorful Gene 
Biological Technology Co., Ltd. (Wuhan, China). 
LysoTracker Green was purchased from Yeasen 
Biotech Co. Ltd. (Shanghai China). Ultrapure water 
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with a resistivity of 18.2 MΩ·cm was used throughout 
the experiments. 
Preparation of the macrophage membranes 
Macrophage membranes were isolated from 
RAW264.7 cells as previously described, with a minor 
modification [30,46]. The RAW264.7 cell membrane 
was obtained using the Membrane Protein Extraction 
kit. Briefly, collected cells were dispersed in 
membrane protein extraction buffer solutions and 
cooled in an ice bath for 15 min. After that, the cell 
suspension was transferred to a glass homogenizer 
and homogenized approximately 30 times. Then, the 
obtained mixture was centrifuged (1500 rpm, 10 min, 
4 °C and 14000 rpm, 30 min) to acquire the cell 
membranes. A bicinchoninic acid (BCA) protein assay 
was employed to analyze the total protein content in 
the obtained macrophage membrane. In order to 
obtain MM vesicles, the extracted macrophage 
membranes were first ultrasonicated for 15 min and 
then extruded 10 times through a 400 nm 
polycarbonate porous membrane using an Avestin 
mini extruder (Avestin, LF-1, Canada). The harvested 
MM vesicles were stored in water at 4 °C. 
Preparation of rapamycin-loaded PLGA 
nanoparticles (RAPNPs) 
RAPNPs were prepared via the nano-
precipitation method as previously described, with a 
slight modification [47,48]. Briefly, RAP (1.5 mg) and 
PLGA (15 mg) were dissolved in DMSO (1 mL). The 
mixture was precipitated by adding 4 mL of water 
dropwise with gentle stirring, and then the mixture 
was transferred to dialyzation (molecular weight 
cut-off (MWCO) of 3500 Da) against water to remove 
free RAP and DMSO. The RAPNP solution was 
quantified and stored at 4 °C. To prepare the 
fluorescently labeled nanoparticles, 0.1 wt% DiD 
(excitation = 644 nm, emission= 665 nm) was loaded 
into PLGA according to the former method (DiDNPs). 
Preparation of MM camouflaged RAPNPs 
(MM/RAPNPs) 
MM/RAPNPs were fabricated by coating 
RAPNPs with MMs by a direct extrusion method. 
Briefly, MM vesicles and RAPNPs were mixed at a 
membrane protein-to-polymer ratio of 1:1 (w/w) and 
sonicated for 3 min in a sonicator bath (FS30D, 42 
kHz, 100 W). The mixture was then extruded 10 times 
through a 200 nm polycarbonate porous membrane 
using an Avestin mini extruder (Avestin, LF-1, 
Canada) to harvest the MM/RAPNPs. 
Characterization of the nanoparticles 
The size, size distribution and zeta potentials of 
RAPNPs, MM vesicles and MM/RAPNPs were 
determined using a Malvern Zetasizer Nano ZS unit 
(Nano ZS 90, Malvern, U.K.) with a He-Ne laser (λ = 
633 nm) at a scattering angle of 90° at 25 °C. A drop of 
NP solution at a concentration of 100 μg/mL was 
deposited onto a glow-discharged carbon-coated grid 
and stained with 1% phosphotungstic acid. 
Subsequently, the morphologies of the RAPNPs and 
MM/RAPNPs were visually observed using 
transmission electron microscopy (TEM) at 200 kV 
(JEM-2100F, JEOL, Japan). 
Identification of the membrane orientation of 
MM/RAPNPs 
The membrane orientation of MM/RAPNPs was 
identified by quantifying the glycoprotein content in 
the MM/RAPNPs as previously reported [49]. Briefly, 
 
 
Figure 1. Schematic of MM/RAPNP fabrication and its treatment for AS. 
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the MMs extracted from 1×107 cells and the 
subsequent MM/RAPNPs were incubated with 
trypsin at room temperature for 2 h to initiate 
trypsinization. Then, the samples were centrifuged at 
8000 rpm for 5 min, and the supernatant was collected 
to quantify the glycoprotein content using a Mouse 
Glycoprotein ELISA Kit following the manufacturer’s 
instructions. 
Characterization of proteins 
The membrane proteins were characterized by 
polyacrylamide gel electrophoresis (SDS-PAGE). The 
membrane proteins of the MM vesicles and 
MM/RAPNPs were extracted by Cell Total Protein 
Extraction kits. The extracted membrane proteins 
were run on a 4-12% Bis-Tris 10-well minigel in 
running buffer using a Bio-Rad electrophoresis 
system at 75 V for 0.5 h and then at 140 V for 1 h. 
Finally, the resulting polyacrylamide gel was stained 
with SimplyBlue overnight for visualization. 
Furthermore, the integrin α4β1 and CD47 
contents in RAW264.7 cells, MMs, MM/RAPNPs and 
RAPNPs were determined by western blot analysis. 
The total protein of the lysis solution from 1 × 107 
RAW264.7 cells, RAPNPs, MMs extracted from 1 × 107 
cells and the subsequent MM/RAPNPs were 
extracted by Cell Total Protein Extraction kits and 
used for measurements. Samples underwent 
electrophoresis on a 10% SDS-polyacrylamide gel and 
were transferred to a polyvinylidene difluoride 
membrane (Millipore, USA). Then, the membranes 
were treated with primary antibodies against α4 
(anti-integrin α4, 8440S, CST), β1 (anti-integrin β1, 
34971, CST), and CD47 (anti-CD47 antibody, 
ab175388, Abcam), followed by horseradish 
peroxidase-labeled goat/anti-rabbit IgG (H+L) 
(Beyotime, Jiangsu, China). The protein signals were 
measured by the enhanced chemiluminescence 
method using a ChemiDoc MP imaging system 
(Bio-Rad, USA). 
Drug loading and in vitro drug release study 
RAPNPs were first frozen at -80 °C and then 
freeze-dried with a Labconco Free Zone lyophilizer. 
Then, the RAPNP lyophilized powder was dissolved 
in DMSO, and the absorbance was measured with a 
UV/Vis spectrophotometer (DU730, Beckman 
Coulter) at 280 nm. According to the preestablished 
standard curve of RAP in DMSO, the drug loading 
efficiency (LE) and drug encapsulation efficiency (EE) 
were calculated as follows: 
𝐿𝐿𝐿𝐿 (%) = 𝑀𝑀𝑅𝑅𝑅𝑅𝑅𝑅
𝑀𝑀𝑅𝑅𝑃𝑃𝑃𝑃𝑅𝑅+𝑀𝑀𝑅𝑅𝑅𝑅𝑅𝑅
× 100%  (1) 
𝐿𝐿𝐿𝐿 (%) =  𝑀𝑀𝑅𝑅𝑅𝑅𝑅𝑅
𝑀𝑀𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎
× 100%   (2), 
where MRAP is the mass of RAP loaded in the 
NPs, MPLGA is the mass of polymer in the formulation 
and Madded is the mass of RAP added. 
The drug (RAP) release from RAPNPs and 
MM/RAPNPs was studied separately using a dialysis 
method. Briefly, RAPNP and MM/RAPNP solutions 
(2 mg/mL, 1 mL each) were added to disposable 
dialysis bags (MWCO: 3500 Da, Thermo Scientific). 
The dialysis bags were then immersed in 10 mL of 
phosphate-buffered saline (PBS) solution (release 
medium, pH 7.4) at 37 °C. Three independent 
replicates were used for each sample. One milliliter of 
release medium was collected for analysis at different 
time intervals and replaced with an equivalent 
volume of fresh PBS at 37 °C. The cumulative amount 
of RAP released was quantified by a UV/Vis 
spectrophotometer (DU730, Beckman Coulter) at 280 
nm. 
Colocalization study 
The MMs were stained using DiO. Then, the 
DiO-labeled MMs were coated onto the DiDNPs by a 
direct extrusion method as previously described. Four 
microliters of sample was added to the coverslip for 
observation by confocal laser scanning microscopy 
(CLSM). For the colocalization study after cell uptake, 
human umbilical vein endothelial cells (HUVECs) 
were maintained in DMEM supplemented with 10% 
fetal bovine serum (FBS) and cultured at 37 °C with 
5% CO2. Then, 150 μg of MM/DiDNPs was added to 
the HUVECs. After incubation for an additional 4 h, 
the cells were washed with PBS three times, fixed 
with tissue fixative for 30 min at room temperature, 
and then the nuclei of the cells were stained with 
4′,6-diamidino-2-phenylindole (DAPI). The cells were 
visualized using CLSM. 
Cellular uptake 
In vitro cellular uptake was evaluated in human 
umbilical vein endothelial cells (HUVECs) and 
RAW264.7 cells. For HUVEC uptake, cells were 
maintained in 1640 medium supplemented with 10% 
FBS. Confluent cells were stimulated with 50 ng/mL 
TNF-α (Gibco) for 24 h to activate HUVECs [26]. Then, 
100 μg of DiDNPs or MM/DiDNPs were added to 
nonactivated or activated HUVECs. After incubation 
for 2 h, the cellular uptake of DiDNPs and MM/ 
DiDNPs was quantified by fluorescence-activated cell 
sorting (FACS) analysis (BD, USA). Cells were also 
stained with DAPI for visualization under by confocal 
laser scanning microscopy (CLSM) (Olympus, Japan). 
To investigate the importance of VCAM-1 on the 
interaction and cellular uptake of MM-coated NPs, 
activated HUVECs were treated with 300 μg/mL 
VCAM-1 antibodies for 1 h before incubation with 
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MM-coated nanoparticles. Then, after incubation with 
100 μg of MM/DiDNPs for 2 h, the cells were stained 
with DAPI for visualization by CLSM. 
Similarly, to evaluate the effects of MM 
camouflaging on phagocytosis reduction by 
macrophages, experiments were performed using 
RAW264.7 macrophage cells. The internalization of 
DiDNPs and MM/DiDNPs by macrophage cells was 
evaluated by CLSM and FACS measurements. Briefly, 
RAW264.7 macrophage cells were seeded in 12-well 
plates at a density of 1×105 cells per well in 1 mL of 
DMEM supplemented with 10% FBS and cultured 
overnight. Then, 150 μg of DiDNPs or MM/DiDNPs 
were added to each well. After incubation for 0.5, 1, 2, 
and 4 h, the nuclei were stained with DAPI for CLSM 
imaging. Cells were collected for quantification by 
FACS analysis. To understand where the 
nanoparticles located to in the cytoplasm, lysosomes 
were stained with 50 nM LysoTracker Green for 2 h 
after the RAW264.7 macrophage cells were incubated 
with 150 μg of DiDNPs or MM/DiDNPs for 4 h. 
Inflammatory cytokine assay in macrophages 
The expression levels of typical inflammatory 
cytokines (tumor necrosis factor-α (TNF-α) and 
interleukin-6 (IL-6)) secreted by macrophages were 
determined. Specifically, RAW264.7 cells were seeded 
in 24-well plates at 1×105 cells per well and cultured 
for 12 h. Then, the control group was treated with 100 
ng/mL LPS. The other groups were first treated 
individually with free RAP, RAPNPs or MM/ 
RAPNPs at various concentrations for 4 h and then 
stimulated with 100 ng/mL LPS for 24 h. Afterwards, 
the expression levels of TNF-α and IL-6 in the culture 
supernatant were determined by ELISA. 
Inhibition of proliferation of macrophages and 
SMCs in vitro 
RAW264.7 cells and smooth muscle cells (SMCs) 
were seeded in a 96-well plate (104 cells per well) and 
cultured in DMEM or 1640 medium containing 0.5% 
FBS for 12 h. Then, the cells were incubated with 
various doses of free RAP, RAP@PLGA, or 
RBC/RAP@PLGA for 24 h. Cell viability was 
quantified by MTS assay. 
Cell cytotoxicity evaluation 
ECs, SMCs and RAW264.7 cells were seeded in 
96-well plates at a density of 1.0×104 cells per well in 
100 μL of culture medium containing 10% (v/v) FBS, 
100 U/mL penicillin, and 100 μg/mL streptomycin. 
Cells were incubated at 37 °C in a humidified 
atmosphere containing 5% CO2 for 12 h before the 
NPs were added. Then, the cells were treated with 
medium containing PLGA NPs or MM-coated PLGA 
NPs (MM/NPs) at various doses. After incubation for 
24 h, cell viability was quantified by MTS assay. 
In vitro blood compatibility tests 
The hemolysis of MM/RAPNPs was tested by a 
direct contact method in vitro as previously reported 
[50]. Briefly, 1 mL of rabbit blood was diluted with 
1.25 mL of 0.9% (w/v) sodium chloride solution. 
Then, 0.1 mL of the diluted whole blood sample was 
added to RAPNPs or MM/RAPNPs solution (5 mL, 1 
mg/mL). Then, the specimens were continuously 
incubated at 37 °C for 1 h. Subsequently, the solutions 
were centrifuged for 5 min at 3000 rpm. The 
absorbance of the supernatant was measured at 540 
nm using a microplate reader (μQuant, Bio-Tek 
Instruments Inc., Winooski, USA) to determine the 
released hemoglobin from lysed red blood cells. 
Untreated 0.9% (w/v) sodium chloride solution and 
double distilled water served as negative and positive 
controls. 
The effect of MM/RAPNPs on platelet activation 
was also detected by measuring the concentration of 
platelet α granule membrane protein (GMP-140) in 
plasma after coincubation with nanoparticles. Briefly, 
anticoagulated whole rabbit blood was centrifuged at 
1000 rpm for 10 min at 4 °C, and the supernatant 
plasma was collected. Then, 10 μL of 1.5 mg/mL 
RAPNP or MM/RAPNP solution was added to 300 
μL of the prepared plasma, while saline was used as 
the control group. The samples were incubated at 37 
°C for 30 min. After incubation, the concentration of 
GMP-140 in plasma was detected with an ELISA kit. 
Animals 
Male C57BL/6 mice and male apolipoprotein E 
knockout (ApoE−/−) mice (eight weeks old) were 
obtained from the Third Military Medical University 
in Chongqing, China. Animals were housed in 
standard mouse cages with ad libitum access to water 
and food. Before experiments, all mice were 
acclimatized for at least 3 days. All animal-related 
procedures were in compliance with the China 
Council on Animal Care and Chongqing University 
protocol for animal use. All ethical guidelines for 
experimental animals were followed. 
In vivo long-term circulation test 
The experiments were performed on adult male 
C57BL/6 mice weighing 25 ± 2 g. Briefly, DiDNPs and 
MM/DiDNPs were injected intravenously (200 μL, 2 
mg/mL), and 30 μL of blood was rapidly collected 
from the tail after 1 min, 1 h, 6 h, 12 h, 24 h, 48 h. Blood 
samples were diluted with 30 μL of PBS containing 
EDTA-K2 in 96-well plates, and the fluorescence was 
measure with a microplate reader (TECAN M1000, 
USA) to determine fluorescence intensity. 
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In vivo targeting to atherosclerotic plaques 
ApoE−/− mice were fed a high-fat diet (HFD, 
consisting of a normal diet containing 0.5% 
cholesterol and 5% lard) for 2 months. DiDNPs and 
MM/DiDNPs were administered via the tail vein at a 
PLGA NP dosage of 2 mg/kg. After 24 h, the mice 
were euthanized and perfused with precooled PBS 
containing 4% paraformaldehyde to remove the blood 
and unbound nanoparticles. Each aorta from the root 
to the iliac bifurcation and the main organs were 
isolated for imaging and fluorescence quantification 
using an Xenogen IVIS 200 system. In addition, 
cross-sections of the aortic roots were observed by 
CLSM after staining with DAPI. 
Treatment of atherosclerosis in ApoE−/− mice 
ApoE−/− mice after 10 weeks of HFD feeding 
were randomized into 4 groups (5 mice per group) 
and dosed for 30 days by tail vein injection every 
three days. In the treatment groups, mice were 
administered free RAP, RAPNPs or MM/RAPNPs in 
5% glucose at a dose of 0.7 mg/kg of RAP. Mice 
treated with only 5% glucose served as the model 
control group. 
Quantitative analysis of the atherosclerotic 
plaques 
At the end stage of the treatment, the ApoE−/− 
mice were euthanized. Pathological evolution was 
evaluated by measuring the lesion area of 
atherosclerotic plaques in the aorta from the heart to 
the iliac bifurcation. Briefly, each aorta was fixed with 
paraformaldehyde (4% in PBS) for 1 h. After the 
periadventitial tissue was cleaned, the aorta was 
opened longitudinally, and then the entire aorta was 
stained with Oil red O (ORO) to quantify the plaque 
area. To determine the atherosclerotic extent at the 
aortic root, tissues embedded in the Tissue Tek® 
O.C.T. Compound (Sakura Finetek USA, Inc.) were 
cross-sectioned serially at 8 μm intervals and stained 
by ORO to quantify the area of the atherosclerotic 
plaques using Nis-Elements BR 3.2 software (Nikon, 
Japan). 
Histology and immunohistochemistry 
The aortic sinus was fixed with para-
formaldehyde (4% in PBS) for 1 h and then embedded 
in paraffin to cut into sections. After deparaffinizing 
and subsequently drying at 60 °C, sections were 
stained with toluidine blue to determine the necrotic 
core. For immunohistochemistry analysis, sections 
were immersed in 3% hydrogen peroxide and 100% 
methanol for 20 min to inhibit the activity of 
endogenous peroxidase and then blocked with 1% 
bovine serum albumin in PBS containing 0.3% Triton 
X-100 for 60 min. Antibodies for CD68, α-smooth 
muscle actin (α-SMA), and CD31 were coincubated 
for quantification of macrophages, SMCs, and ECs, 
respectively. The main organs, including the heart, 
liver, spleen, lung and kidney, were also harvested, 
fixed in paraformaldehyde (4% in PBS), and then 
sectioned for histology analysis by hematoxylin-eosin 
(H&E). 
Tissue sample morphometry criteria for 
analyzing aortic cross-sections were based on 
previously described methods [51]. For lipid 
deposition and necrotic core analysis, slides from 5 
different mice per group were analyzed. For each 
ORO or toluidine blue stained slide, the vessel area, 
lipid deposition area and necrotic core areas were 
measured manually using ImageJ software. 
Additionally, the proportion of lipid area or necrotic 
core areas in each sample was calculated by dividing 
the vessel area by the lipid area or necrotic core areas. 
For the immunohistochemistry analyses of CD68 and 
α-SMA, slides from 5 different mice per group were 
analyzed. For each slide, the CD 68 or α-SMA 
positively stained cells within the atherosclerotic 
plaque areas were counted, and the plaque areas were 
measured using ImageJ software. The final cell count 
from each sample was divided by the plaque area to 
obtain a final cell density. All samples and groups 
were analyzed using the same parameters to maintain 
objectivity and eliminate bias. Lipid deposition and 
necrotic core percentage as well as the relative 
number of macrophages and SMCs were analyzed 
independently using 2-way repeated-measures 
ANOVA with a single pooled variance and Tukey’s 
correction for pairwise comparisons within groups for 
each data set. 
Complete blood count and clinical chemistry 
Blood was collected in EDTA spray-coated tubes 
and immediately analyzed for hematological 
parameters by an automated hematology analyzer 
(Sysmex KX-21, Sysmex Co., Japan), such as RBCs, 
platelets (PLTs), hemoglobin (HGB), white blood cells 
(WBCs), lymphocytes, monocytes and neutrophils. 
The plasma concentrations of alanine amino-
transferase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALP), creatinine (CREA), blood 
urea nitrogen (UREA), high-density lipoprotein 
(HDL), low-density lipoprotein (LDL), triglycerides 
(TGs) and total cholesterol (TC) were quantified by an 
automated analyzer platform (Roche Cobas C501, 
Roche Co., Switzerland). 
Statistical analysis 
GraphPad Prism version 6.0 software 
(GraphPad, USA) was used for statistical analysis. 
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Data analysis was performed using one-way analysis 
of variance (ANOVA). The minimum significance 
levels were set at *p < 0.05, **p < 0.01 and ***p < 0.001, 
with all data displayed as the mean ± SD. 
Results and Discussion 
Fabrication and characterization of 
MM/RAPNPs 
MM/RAPNPs were constructed using a 
three-step method: (i) preparation of the RAP-loaded 
PLGA nanoparticles (RAPNPs), (ii) isolation of the 
macrophage membrane (MM), and (iii) camouflage of 
the RAPNPs with the macrophage membrane. 
RAPNPs were first prepared by the nanoprecipitation 
method [47]. Our results showed that the drug 
loading efficiency (LE) and encapsulation efficiency 
(EE) of RAPNPs were 6.87% and 76.3%, respectively 
(Table S1), indicating that hydrophobic RAP was 
efficiently encapsulated into the NPs. Dynamic light 
scattering (DLS) analysis indicated that the 
hydrodynamic diameter of RAPNPs was 95.69 nm 
with a favorable polydispersity index (PDI) of 0.110 
(Figure 2A), and the zeta potential of RAPNPs was 
-26.4 mV (Figure 2B). Transmission electronic 
microscopy (TEM) measurements showed that the 
morphology of the RAPNPs particles was spherical 
with an average diameter of approximately 90 nm 
(Figure 2C). These results confirm that RAP-loaded 
PLGA nanoparticles are successfully prepared by the 
nanoprecipitation method. 
To harvest MM/RAPNPs, RAPNPs were mixed 
with freshly prepared MM vesicles and subsequently 
extruded through a 200 nm porous polycarbonate 
membrane. Compared to uncoated RAPNPs, the 
hydrodynamic diameter of MM/RAPNPs increased 
from 95.69 to 110.8 nm, which was ascribed to the MM 
with a thickness of approximately 8 nm (Figure 2A). 
Additionally, the zeta potential of MM/RAPNPs 
(-41.7 mV) was comparable to that of the original MM 
(-43.4 mV) but much higher than that of the 
unmodified RAPNPs (-26.4 mV) (Figure 2B). The 
visual TEM image results confirmed that 
MM/RAPNPs showed a uniform “core-shell” 
structured morphology (Figure 2C). Furthermore, the 
single outer layer of the MM “shell” was 
approximately 8 nm thick, which agreed well with the 
previously reported thickness of the macrophage 
membrane [30,32]. The MM coating on nanoparticles 
was also investigated by CLSM. Instead of RAP, the 
DiD fluorophore was loaded into the PLGA “core”, 
and the MM was labeled by DiO. As shown in Figure 
S1, the green membranes and red DiDNPs exhibited a 
high degree of colocalization, indicating the 
successful coating of MM on the DiDNPs. To further 
verify the stability of the “core-shell” structured 
nanoparticle, the fluorescently labeled NPs were 
incubated with HUVECs. The fluorescence images 
showed that the red fluorescence from DiD 
(representing the PLGA “core”) and the green 
fluorescence of DiO (representing the MM “shell”) 
colocalized well (Figure 2D), suggesting that 
MM/RAPNPs exhibited favorable stability even after 
cell internalization. After long-term storage at room 
temperature, MM/RAPNPs also showed a relatively 
constant size (Figure S2) in water and medium 
containing 10% FBS for 48 h, indicating satisfactory 
stability. In addition, the protein profiles in the MMs 
and MM/RAPNPs were determined by SDS-PAGE. 
The protein composition in the MM was mostly 
retained in the MM/RAPNPs, but no protein signal 
was detected from the RAPNPs (Figure S3), 
suggesting the successful translocation and retention 
of natural macrophage cell membranes onto the 
RAPNP surface. Moreover, due to the exclusive 
distribution of glycoproteins on the outside surface of 
the cell membranes, the orientation of the MM on the 
surface of the nanoparticles could be evaluated by 
quantification of the glycoproteins [49]. As shown in 
Figure S4, the average glycoprotein content on 
MM/RAPNPs was approximately 92.95% of the 
amount in free MMs. This quantification suggests that 
the glycoproteins are strongly retained on the outside 
surface of the MM/RAPNPs, confirming their 
intrinsic “right-side-out” orientation when MMs are 
coated onto the nanoparticles. According to previous 
reports, the protein integrin α4β1 on the macrophage 
surface can specifically recognize and bind VCAM-1 
[30,40]. Therefore, markers on macrophages, purified 
MMs, MM/RAPNPs and RAPNPs were detected by 
western blot measurements to determine the quality 
of the purified MMs and the effective decoration of 
the MMs on the MM/RAPNPs. The specific protein 
signals of integrin α4 and integrin β1 were observed 
in macrophages, MMs, and MM/RAPNPs, which 
validated the presence of these integrin markers 
(Figure 2E). In addition, the CD47 protein, which 
plays a key role in regulating macrophage 
phagocytosis by bonding with the SIRP-α receptor, 
was also detected [52]. The results clearly showed that 
CD47 was retained on the MM and MM/RAPNPs 
(Figure 2E). Moreover, the protein signals of integrin 
α4, integrin β1 and CD47 were not detected in the 
RAPNPs. Collectively, this evidence suggests not only 
the successful decoration of RAPNPs with MMs to 
form MM/RAPNPs but also the retention of 
functional proteins to develop stealthy and targeted 
effects for potential advanced drug delivery. 
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Figure 2. Characterization of the MM-coated biomimetic nanoparticles. (A) The sizes and (B) zeta potentials of MMs, RAPNPs and MM/RAPNPs (n = 3, mean ± SD). (C) TEM 
images of RAPNPs and MM/RAPNPs (scale bar = 100 nm). (D) CLSM images of the colocalization of the nucleus (blue), MM “shell” (green) and PLGA “core” (red) (scale bar = 
5 µm). (E) Western blot results of integrin α4, integrin β1 and CD47 in macrophages, MMs, MM/RAPNPs and RAPNPs. (F) In vitro drug release profiles of RAPNPs and 
MM/RAPNPs (n = 3). 
 
The release kinetics of RAP from RAPNPs and 
MM/RAPNPs were investigated in buffer solutions 
that simulated the extracellular environment (PBS, pH 
7.4). After 72 h of incubation, 38.51% and 35.62% of 
RAP was released from RAPNPs and MM/RAPNPs, 
respectively. Compared to RAPNPs, MM/RAPNPs 
showed a slightly slower RAP release profile (Figure 
2F). In general, the steady and long-term RAP release 
behavior of MM/RAPNPs indicates their potential to 
be used for sustained drug release. 
Characterization of the immune-evasive 
functions and targeted delivery in vitro 
Accumulating evidence shows that MM-coated 
nanoparticles can inhibit phagocytosis by macro-
phage cells [30-32]. The cellular phagocytosis of 
MM/DiDNPs was evaluated in RAW264.7 cells. The 
CLSM images showed that both DiDNPs and MM/ 
DiDNPs were internalized by macrophages in a time- 
dependent manner. However, after internalization by 
macrophages, stronger red fluorescence from the 
DiDNPs was detected than the fluorescence from 
MM/DiDNPs at the same time (Figure 3A). This was 
further confirmed by FACS analysis using 
fluorescence quantification. After 0.5, 1, 2, and 4 h of 
incubation, the fluorescence-calculated internalization 
content of DiDNPs was approximately 2.5, 3.2, 2.0 and 
2.4 times higher than that of the MM/DiDNPs, 
respectively (Figure 3B-D). In addition, staining of the 
lysosomes by LysoTracker (green fluorescence) 
revealed endolysosomal trafficking of most 
internalized DiDNPs and MM/DiDNPs in RAW264.7 
cells because the red nanoparticles and green 
lysosomes exhibited a high degree of colocalization in 
both DiDNP- and MM/DiDNP-treated cells (Figure 
S5). The results demonstrate that the MM/DiDNPs 
can significantly inhibit internalization by 
macrophages, which is a great benefit to prolong their 
blood circulation time during bloodstream delivery 
by reducing undesirable clearance. 
The decorated MMs influencing cellular uptake 
were evaluated using HUVECs. HUVECs activated 
with TNF-α could overexpress VCAM-1 [26], 
ensuring the interaction specificity with integrinα4β1 
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on the macrophages. The cellular uptake of the 
DiDNPs and MM/DiDNPs was visually observed by 
CLSM and further quantified by FACS. The CLSM 
images showed that MM/DiDNPs displayed a higher 
internalization within activated endothelial cells 
compared with DiDNPs, showing stronger red 
fluorescence signals (Figure 3E). Moreover, FACS 
analysis showed that the cellular uptake of 
MM/DiDNPs in activated endothelial cells had a 
3.0-fold higher signal than that of DiDNPs (Figure 3F, 
G). In addition, after using VCAM-1 antibodies to 
block VCAM-1 on activated HUVECs, the uptake of 
MM/DiDNPs by activated endothelial cells was 
obviously weakened. This indicates that VCAM-1 on 
HUVECs plays an important role in the interaction 
and cellular uptake of MM-coated NPs (Figure S6). In 
general, MM decoration on MM/DiDNPs enhanced 
the cellular uptake of MM/DiDNPs in activated 
endothelial cells, indicating a feasible strategy for 
targeted drug delivery in AS. 
In vitro cytotoxicity and blood compatibility  
Subsequently, we evaluated the in vitro 
biological effects of MM-coated nanoparticles. The 
cytotoxicity of PLGA NPs and MM-coated NPs in 
ECs, SMCs and RAW264.7 cells was investigated. As 
shown in Figure 4A-C, after 24 h of incubation with 
PLGA NPs and MM/NPs at the doses of 10, 50, or 200 
μg/mL, no significant changes in cell viability were 
observed compared to the control. These results 
suggested that both PLGA NPs and MM/NPs 
exhibited good cytocompatibility. 
Blood compatibility is an important safety index 
of biomaterials, especially those that are in direct 
contact with blood [53]. Therefore, we tested the blood 
compatibility of MM/RAPNPs in vitro. First, the 
hemolysis of MM/RAPNPs was detected by the direct 
contact method. The visual hemolytic images showed 
no significant hemolysis of either RAPNPs or 
MM/RAPNPs at a concentration of 1 mg/mL (Figure 
4D). The OD values of RAPNPs and MM/RAPNPs 
were not significantly different from those of the 
negative control group (Figure 4E). The results 
showed that RAPNPs and MM/RAPNPs are 
nonhemolytic. 
Furthermore, the effects of MM/RAPNPs on 
platelet activation were also detected by measuring 
the concentration of GMP-140 in plasma after 
coincubation with NPs. The concentration of 
GMP-140 in the RAPNP and MM/RAPNP groups 
showed little difference compared with the negative 
control group (Figure 4F), indicating that RAPNPs 
and MM/RAPNPs were safe enough to avoid 
undesirable platelet activation. Therefore, the results 
confirmed that both RAPNPs and MM/RAPNPs have 
good blood compatibility. 
 
 
Figure 3. Cellular uptake by macrophages and HUVECs. (A) CLSM images of DiDNPs and MM/DiDNPs internalized by RAW264.7 cells (scale bar = 10 µm). FACS results of 
cellular uptake of (B) DiDNPs and (C) MM/DiDNPs in RAW264.7 cells. (D) Quantification of cellular uptake of DiDNPs and MM/DiDNPs in RAW264.7 cells (n = 3, mean ± SD). 
Cellular uptake of DiDNPs and MM/DiDNPs in HUVECs either in unactivated (Non-acti ECs) or activated (Acti-ECs) with tumor necrosis factor alpha (TNF-α) as demonstrated 
by (E) CLSM (scale bar = 20 µm), (F) FACS (1. blank; 2. Non-acti ECs + MM/DiDNPs; 3. Non-acti ECs + DiDNPs; 4. Acti ECs + MM/DiDNPs; 5. Acti ECs + DiDNPs ) and (G) 
fluorescent quantification of FACS (n = 3, mean ± SD). (**p < 0.01 and ***p < 0.001, ns, no significance.) 
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Figure 4. In vitro cytotoxicity and blood compatibility studies. Cell viability of (A) ECs, (B) SMCs and (C) RAW264.7 cells after incubation with various doses of NPs for 24 h. (D) 
Images of the hemolysis test with RAPNPs and MM/RAPNPs. (E) The absorbance of RAPNPs and MM/RAPNPs measured at 540 nm (n = 3, mean ± SD). (***p < 0.001; ns, no 
significance). (B) The concentration of platelet α-granule membrane protein (GMP-140) in plasma after incubation with different samples (n = 3, mean ± SD.) 
 
In vitro antiatherosclerotic effects 
The proinflammatory cytokines secreted by 
macrophages are the primary factor involved in the 
pathogenesis of atherosclerosis [35]. Accordingly, the 
capability of NPs to alleviate the expression of the 
inflammatory cytokines in macrophages was 
determined in vitro. As shown in Figure S7, the levels 
of typical proinflammatory cytokines, including 
TNF-α and IL-6, were remarkably downregulated in 
the cells treated with RAPNPs or MM/RAPNPs, 
which was attributed to the satisfactory 
anti-inflammatory effects of RAP. Moreover, since the 
proliferation of macrophages and SMCs plays an 
important role in atherosclerosis progression [37,54], 
we examined whether RAP-loaded nanoparticles 
inhibit the proliferation of RAW264.7 cells and SMCs 
in vitro. As shown in Figure S8, RAP inhibited the 
viability of macrophages and SMCs in a dose- 
dependent manner. Moreover, at the same dose, 
RAPNPs and MM/RAPNPs showed comparable 
inhibition of cell proliferation. The slightly more 
potent antiproliferative activity of free RAP might be 
ascribed to the slower RAP release from RAPNPs and 
MM/RAPNPs. Collectively, these data demonstrated 
that MM/RAPNPs can attenuate LPS-induced 
inflammation and inhibit the proliferation of 
macrophages and SMCs, suggesting the significant 
potential of these biomaterials for atherosclerosis 
therapy. 
In vivo targeting of atherosclerotic plaques 
To assess whether MM/DiDNPs inherited a long 
circulation lifetime from the natural MMs, we studied 
the pharmacokinetics in vivo in a C57BL/6 mouse 
model. After intravenous injection via the tail vein, the 
residual content of the nanomedicine was evaluated 
by measuring the relative signal intensity of the 
collected blood at certain time interval using 
fluorescence spectroscopy. Compared with the bare 
DiDNPs, the MM/DiDNPs could significantly 
enhance the blood retention time over a span of 48 h. 
Interestingly, more than 15% of MM/DiDNPs were 
retained in blood vessels even after 48 h of blood 
circulation, whereas the bare DiDNPs were almost 
eliminated from the blood at 8 h postinjection (Figure 
5A). Therefore, the MM/DiDNPs exhibited superior 
blood retention, suggesting that the immuno-
suppressive surface makeup of the MM is able to 
efficiently prolong the blood circulation time to 
potentially enhance targeted drug delivery for AS. 
The targeting ability of the MM/DiDNPs to the 
atherosclerotic regions was assessed in the ApoE−/− 
mouse model. After 24 h of intravenous 
administration of the DiD-loaded nanoparticles, the 
mice were sacrificed, and their main organs and 
aortas were harvested and processed ex vivo. The 
MM/DiDNPs accumulated in the atherosclerotic 
plaques could be clearly observed by ex vivo imaging. 
Strong fluorescence was found in the regions of the 
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aortic arc, a region prone to developing 
atherosclerosis (Figure 5B). By contrast, the DiDNP 
group showed relatively weak fluorescence in the 
atherosclerotic plaque regions, which was much 
lower than that of the MM/DiDNP group (Figure 5C). 
In addition, the fluorescence images of the 
cross-sections from the plaque regions showed that 
accumulated MM/DiDNPs were largely localized 
within plaque regions (Figure 5D). This result 
demonstrated that MM functionalization could 
enhance MM/DiDNP accumulation within plaque 
regions in vivo. In addition, at 24 h postinjection, the 
fluorescence signals were mainly distributed in the 
liver, kidney and lung (Figure S9A). The fluorescence 
signals in the liver and kidney of the MM/DiDNPs 
group were significantly lower than those in the 
DiDNPs group (Figure S9B). This result confirms that 
NPs coated with MMs can reduce the accumulation of 
NPs in the main organs in vivo, which could reduce 
the nonspecific toxicity and side effects of MM-coated 
NPs. 
It is well documented that dysfunctional 
endothelium is the main pathological feature in 
atherosclerotic areas. Specifically, dysfunctional 
endothelial cells express adhesion molecules (e.g., 
VCAM-1) and secrete chemokines to recruit 
circulating monocyte macrophages and promote them 
to traverse the subendothelial space and migrate into 
the intimal layer [55,56]. In addition, macrophages are 
large, highly versatile white blood cells that 
intrinsically work as major cellular effectors in 
inflammation and tissue repair processes [28,57]. 
There are proteins (e.g., integrin α4β1) on the surface 
of macrophage membranes that can interact with 
 
 
Figure 5. Targeting atherosclerotic plaques in ApoE−/− mice. (A) Relative fluorescence intensity of DiDNPs and MM/DiDNPs in blood. (B) Representative ex vivo fluorescence 
images and (C) quantitative data of DiD fluorescent signals accumulated in the aorta 24 h postinjection (n =3, mean ± SD, **p < 0.01 and ***p < 0.001, ns, no significance). (D) 
CLSM images of accumulated MM/DiDNPs in atherosclerotic plaques of an aortic root section in ApoE−/− mice (AS plaque outlined by white dashed line, scale bar = 60 µm.) 
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dysfunctional endothelial cells through integrin- 
mediated adhesive interactions, such as the integrin 
α4β1/VCAM-1 interaction [30,40]. Therefore, MM- 
coated NPs that inherit functional proteins of 
macrophage membranes can actively target 
dysfunctional endothelium. Moreover, the EPR effect 
also exists in atherosclerotic lesions based on the leaky 
endothelium from inflammation and the leaky 
microvessels in atherosclerotic plaques, which allows 
nanoparticles to permeate the vascular wall and 
accumulate within the pathological lesion [58,59]. 
Overall, MM-coated NPs with long circulation and 
specific interactions with dysfunctional endothelium 
have the ability to efficiently target and accumulate in 
atherosclerotic lesions. 
In vivo therapeutic efficacy 
The influence of MM/RAPNPs on AS 
development was analyzed in an AS pathological 
model in ApoE−/− mice. After 30 days of treatment, 
the aortas were isolated and stained with ORO 
(Figure 6A). The en face micrographs of ORO-stained 
aortas showed that MM/RAPNP treatment potently 
inhibited the progression of atherosclerotic lesions in 
ApoE−/− mice (Figure 6B and Figure S10). To 
quantitatively evaluate the atherosclerotic lesion, the 
lesion-to-aorta area ratio was calculated. As shown in 
Figure 5C, there were no significant therapeutic 
effects from free RAP treatment compared with the 
control group. It is well known that RAP, a 
biopharmaceutical classification system (BCS) class II 
drug, is practically insoluble in water [44]. Its poor 
solubility resulted in the low bioavailability when 
administered by tail vein injection. Compared with 
free RAP and RAPNPs, which resulted in 18.3% and 
14.43% atherosclerotic lesions, respectively, MM/ 
RAPNPs yielded significantly lower atherosclerotic 
lesions (6.59%) (Figure 6C). 
To further investigate lipid deposition and the 
formation of necrotic areas in atherosclerotic plaques, 
cross-sections of the aortic root were stained with 
ORO and toluidine blue, respectively. According to 
the ORO-stained cross-sections of the aortic root, a 
large amount of lipids (up to 36.45%) were deposited 
in the plaques of the control group (Figure 7A, B). 
Compared with the control group (5% glucose), the 
extent of lipid deposition was reduced in the free RAP 
and RAPNP groups (31.54% and 29.05%, 
respectively). Most notably, after treatment with 
MM/RAPNPs, a reduced amount of lipids (17.41%) 
were found in the plaques (Figure 7A, B). 
Furthermore, toluidine blue staining showed that 
large acellular cores and massive cholesterol crystals 
were found in the plaques of the control group, with 
an average area of necrotic cores of 15.79% (Figure 7C, 
D). The average area of necrotic cores decreased to 
13.57%, 9.00% and 2.95% in the free RAP, RAPNP and 
MM/RAPNP treatment groups, respectively (Figure 
7C, D). These results reveal that MM/RAPNPs can 
effectively attenuate the progression of 
atherosclerosis. 
 
 
Figure 6. Therapeutic efficacy of atherosclerosis in ApoE−/− mice. (A) Schematic of the experimental design in this study. (B) Representative photographs of en face ORO-stained 
aortas. (C) Quantitative analysis of the lesion area (n = 5, mean ± SD). (**p < 0.01, ***p < 0.001 and ns, no significance.) 
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Figure 7. (A) ORO-stained cross-sections of aortic roots (scale bar = 500 µm). (B) Quantitative analysis of the lipid deposition area in the cross-sections of the aortic root (n 
= 5, mean ± SD). (C) The necrotic core areas stained by toluidine blue (scale bar = 500 µm). (D) Quantitative analysis of the necrotic cores of plaque lesions in cross-sections 
of the aortic root (n = 5, mean ± SD). (**p < 0.01, ***p < 0.001 and ns, no significance.) 
 
Figure 8. Representative immunohistochemistry staining photographs with antibodies against (A) CD68 and (C) α-SMA (scale bar = 500 µm). Quantitative analysis the relative 
number of (B) macrophages and (D) SMCs in plaque lesions of cross-sections of the aortic root (n = 5, mean ± SD). (*p < 0.05, **p < 0.01, ***p < 0.001 and ns, no significance.) 
 
To further study the therapeutic mechanism of 
MM/RAPNPs, macrophages and SMCs in 
atherosclerotic lesion areas were investigated by 
immunohistochemistry. Previous studies have 
reported that the abnormal proliferation of 
macrophages and SMCs promotes the progression of 
atherosclerosis [37,54]. Immunohistochemistry 
analyses for CD68 (macrophage marker) (Figure 8A, 
B) and α-SMA (SMC marker) (Figure 8C, D) showed 
that the number of macrophages and SMCs 
dramatically decreased in aortic root sections, 
particularly in the MM/RAPNP-treated group. 
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Immunohistochemistry analyses for CD31 (a marker 
for ECs) showed notable expression of CD31 in the 
vascular endothelium of the aortas from mice treated 
with MM/RAPNPs (Figure S11), which indicated that 
MM/RAPNP treatment might maintain the integrity 
of the vascular endothelium. These results 
substantiated that MM/RAPNPs could significantly 
inhibit the growth of macrophages and SMCs in 
atherosclerotic areas to delay the progression of AS. 
The above results demonstrate the remarkable 
efficacy of MM/RAPNPs in targeting AS treatment. In 
general, the macrophage membrane coating strategy 
endows MM/RAPNPs with the functions of 
long-term circulation and active targeting to the 
dysfunctional endothelium, allowing MM/RAPNPs 
to efficiently accumulate at atherosclerotic lesions. 
Then, the loaded RAP is released from the 
MM/RAPNPs, thereby increasing the local drug 
concentration to inhibit the proliferation of 
macrophages and SMCs and the inflammatory 
responses in the lesion, finally significantly 
attenuating the progression of atherosclerosis. 
Biosafety assessment 
During drug treatment, toxic side effects to 
normal organs and the whole system of nanoparticles 
have been major problems [60]. To assess biosafety, 
the potential side effects were investigated after one 
month of treatment. Complete blood count implied 
that red blood cells (RBCs), platelets (PLTs), and 
hemoglobin (HGB) displayed no significant variations 
(Figure 9A-C). Specifically, the counts of immune- 
 
 
Figure 9. Preliminary safety evaluation. (A-D) Typical hematological parameters (n = 5, mean ± SD). (E-H) Biochemical markers relevant to hepatic and kidney function (n = 5, 
mean ± SD). (I) H&E stained sections of major organs resected from mice subjected to treatment with various formulations for one month (scale bar = 100 µm). 
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associated cells, including white blood cells (WBCs), 
monocytes, lymphocytes and neutrophils, in the 
blood of the treated mice were similar to those of the 
mice in the control group (Figure 9D and Figure S12). 
Clinical biochemistry analysis showed normal levels 
of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), blood urea nitrogen (BUN) 
and creatinine (CRE), indicating that the biological 
functions of the liver and kidney were not affected by 
treatment (Figure 9E-H). Additionally, the levels of 
high-density lipoprotein cholesterol (HDL), low- 
density lipoprotein cholesterol (LDL), total cholesterol 
(TC) and triglycerides (TGs) were not significantly 
altered during the treatment (Figure S13). The results 
of H&E staining also indicated that no significant 
changes or injuries could be found in the main organs, 
further confirming their biocompatibility (Figure 9I). 
Accordingly, MM/RAPNPs had no obvious 
immunotoxicity or side effects after long-term 
treatment, making MM/RAPNPs a safe potential 
candidate for chronic vascular disease therapy. 
Moreover, in our study, RAW264.7 cells were used as 
a model macrophage cell line to extract membranes, 
and the in vitro and in vivo experimental results 
supported the validity of this model. However, 
primary macrophages such as bone marrow-derived 
macrophages might act as a better macrophage model 
and membrane source to fabricate macrophage-based 
biomimetic drug delivery systems. 
Conclusions 
In this study, we developed a biomimetic 
targeted nanoparticle to efficiently and safely inhibit 
the progression of atherosclerosis. In our 
nanoformulation, MMs were coated onto RAPNPs, 
which showed favorable sustained drug release 
kinetics, effectively inhibited macrophage 
phagocytosis and targeted activated endothelial cells 
in vitro. In the AS mouse model, MM-camouflaged 
NPs can efficiently accumulate in atherosclerotic 
plaques. Additionally, in vivo therapy results illustrate 
that MM/RAPNPs significantly delayed the 
progression of atherosclerosis after treatment for one 
month. Finally, the biomimetic nanoparticles 
displayed a good safety profile without any 
significant side effects after long-term administration 
in mice. Therefore, these MM-functionalized 
biocompatible NPs represent new potential 
nanocarriers that hold considerable promise as an 
effective targeted drug delivery system to treat 
atherosclerosis. 
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